Paula Green Sells 1,259 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,259 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the transaction, the senior vice president now directly owns 132,014 shares in the company, valued at approximately $6,514,890.90. This represents a 0.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Paula Green also recently made the following trade(s):

• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $12,661.80.
• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $64,656.00.

Twist Bioscience Trading Up 3.2 %

TWST traded up $1.64 on Wednesday, reaching $53.66. The company had a trading volume of 942,523 shares, compared to its average volume of 781,392. The company has a market capitalization of $3.19 billion, a P/E ratio of -14.91 and a beta of 1.87. The company has a fifty day moving average of $48.63 and a 200-day moving average of $46.21. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same period last year, the firm posted ($0.75) earnings per share. The business’s revenue was up 24.1% on a year-over-year basis. Research analysts predict that Twist Bioscience Co. will post -2.27 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Leerink Partners lifted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Scotiabank upped their target price on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday. TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. AQR Capital Management LLC grew its holdings in Twist Bioscience by 83.9% during the second quarter. AQR Capital Management LLC now owns 61,428 shares of the company’s stock worth $3,027,000 after acquiring an additional 28,027 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Twist Bioscience by 3.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock valued at $1,531,000 after purchasing an additional 1,104 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Twist Bioscience by 407.1% in the 3rd quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock worth $495,000 after purchasing an additional 8,797 shares during the last quarter. CWM LLC lifted its stake in Twist Bioscience by 141.9% during the third quarter. CWM LLC now owns 5,894 shares of the company’s stock valued at $266,000 after purchasing an additional 3,457 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Twist Bioscience by 30.1% during the third quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company’s stock worth $910,000 after buying an additional 4,661 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.